Refractory period (sex) autonomic feedback mechanism, rather than through central chemicals like oxytocin, serotonin, and prolactin. Autonomic feedback is already known to regulate other physiologic systems, such as breathing, blood pressure, and gut motility. This theory suggests that after male ejaculation, decreased wall tension in structures such as the seminal vesicles leads to a change in the fine autonomic signals sent from these organs, effectively creating a negative feedback loop. Such a mechanism is similar to decreased gastric and bowel motility once gastric contents have passed through. Once the feedback loop has been created, the refractory period remains until the loop is broken
Cabazitaxel mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%). Cabazitaxel Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy. Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment. In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival